Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial

BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia. Standard antimicrobial treatment with oral rifampicin 10 mg/kg plus intramuscular streptomycin 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Richard O, Robert, Jérôme, Abass, Kabiru Mohamed, Thompson, William, Sarfo, Fred Stephen, Wilson, Tuah, Sarpong, Godfred, Gateau, Thierry, Chauty, Annick, Omollo, Raymond, Ochieng Otieno, Michael, Egondi, Thaddaeus W, Ampadu, Edwin O, Agossadou, Didier, Marion, Estelle, Ganlonon, Line, Wansbrough-Jones, Mark, Grosset, Jacques, Macdonald, John M, Treadwell, Terry, Saunderson, Paul, Paintsil, Albert, Lehman, Linda, Frimpong, Michael, Sarpong, Nanaa Francisca, Saizonou, Raoul, Tiendrebeogo, Alexandre, Ohene, Sally-Ann, Stienstra, Ymkje, Asiedu, Kingsley B, van der Werf, Tjip S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181188/
https://www.ncbi.nlm.nih.gov/pubmed/32171422
http://dx.doi.org/10.1016/S0140-6736(20)30047-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181188/
https://www.ncbi.nlm.nih.gov/pubmed/32171422
http://dx.doi.org/10.1016/S0140-6736(20)30047-7

Ejemplares similares